Q-TWiST Analysis of Sacituzumab Govitecan vs. Chemotherapy in Previously Treated Patients with HR+/HER2- Metastatic Breast Cancer

By sjmartinez • March 27, 2025

Rugo HS, Bardia A, Schmid P, Tolaney SM, Dasgupta A, Kaushik A, Verret W, Gosset M, Brufsky A, Cortés J, Marmé F. Q-TWiST Analysis of Sacituzumab Govitecan vs. Chemotherapy in Previously Treated Patients with HR+/HER2- Metastatic Breast Cancer. Curr Oncol. 2025 Mar 15;32(3):169. doi: 10.3390/curroncol32030169. PMID: 40136373; PMCID: PMC11941552.

Tags: antibody-drug conjugate, breast cancer, Hematology/Oncology, HR+/HER2−, Publications, Q-TWiST, Quality of Life, Sacituzumab govitecan

Phase Ib/II trial of talimogene laherparepvec alone and with pembrolizumab in advanced solid tumors with liver metastases and hepatocellular carcinoma

Hecht JR, Oberoi A, Garralda Cabanas E, Jae Chon H, Digklia A, Rottey S, Martin Jimenez M, Chaney M, Hippenmeyer J, Lawrence T, Liu K,[...]

Biology, care, and outcomes of gestational breast cancers: a review

Duggirala N, Zhang S, Master A, Rao R, Kapoor NS, Bardia A, Lipsyc-Sharf M. Biology, care, and outcomes of gestational breast cancers: a review. Breast[...]

Yoo C, Ueno M, Klümpen HJ, Kelley RK, Vogel A, Furuse J, Ren Z, Yau T, Chan SL, Ozaka M, Oh SC, Gu S, Park[...]